China Biologic Products Holdings Inc

China Biologic Products — Investor Presentation (March 2011)

28 slides from China Biologic Products's investor presentation, Mar 7, 2011

  1. Slide 1: China Biologic Products, Inc. – March 2011

    March 2011 ’, China Biologic Products, Inc. A profitable, rapidly growing plasma-based biopharmaceutical products company in China

  2. Slide 2: Safe Harbor Statement

    Safe Harbor Statement Cautionary Statement Regarding Forward-looking statements This presentation includes or incorporates by reference statements that constitute forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities

  3. Slide 3: Company Overview

    @o@ Company Overview Largest independent plasma China Biologic Products, Inc. company in China ¢ Operations in 3 provinces with a combined population of over 160 Shandong Taibang | Guizhou Taibang million people Biological Products Biological haat) Co., Ltd. Products Co., Ltd. ¢ Top ranked player in

  4. Slide 4: Fully-Integrated Plasma-based Biopharmaceutical Company

    Plasma Collection 17 plasma collection centers in operation out of an estimated 140 in China; 2 centers currently under construction Manufacturing Fractionation Indirect ownership in 3 out of 32 approved sites in China fa Ela —————— “F lly-Integrated Plasma-based Broad-based plasma derived products

  5. Slide 5: Investment Highlights

    @®@ Investment Highlights Blood products are critical and cannot be substituted in the treatment of medical emergencies and some potentially life-threatening diseases Revenue US$ in millions « Demand outstrips supply « Tight government regulations create favorable conditions for leading industry pla

  6. Slide 6: Mandates Strengthen Market Structure & Drive Consolidation

    Viandates Strengthen rkefiStruieture & Drive Consolidation = Government Reform of Plasma-based Industry + Reform of plasma collection stations in 2006 + GMP Certification required for plasma collection stations, biopharmaceutical manufacturers + Restriction of imported products due to past outbreaks

  7. Slide 7: Plasma Collection

    Plasma Collection = Rapid Decline in Total Collected Plasma in China Due to Government Instituted Reforms 2005 2009 5,000 metric tons metri Collected plasma in Chinaby offers 80.0% Plasma stations Shandong Taibang Plasma stations sourcing from: 3 Shandong & GuizhouTaibang owned: 13 (or 600 metric to

  8. Slide 8: What is Plasma?

    Blood Platelets| TQ . Red Cells Plasma (55%) White biood cel and platelets Red blood cells What is Plasma? Centrifugation process to separate plasma Rest of Blood Plasma Freeze (-300C) China Biologic Products, Inc. 8

  9. Slide 9: Growing Market Opportunity

    Growing Market Opportunity + Rapid expansion in China’s pharmaceutical market + Pharmaceutical market expected to grow at 20%+ pace annually through 2013 (is Heath, Oct 2009). + Drivers include higher health standards, aging population, government spending, rising disposable incomes, accelerating ur

  10. Slide 10: Shandong Taibang is one of first plasma-based manufacturers in China to receive GMP certification

    Shandong Taibang is one of first plasma-based manufacturers in China to receive GMP certification (1999); renewed in 2008 + High barrier to entry: as of 1999, GMP certification is no longer granted to new blood products manufacturers + Stricter inspection standards imposed in January 2008, increasin

  11. Slide 11: Product Revenue Mix

    Product Revenue Mix = Increasing product diversification and growth in higher margin products Bot % of PRODUCTS BSH, | 2009 Sales" An Human Albumin® 47.3% 49.7% 33.2% 36.8% 59% 40% 32% 22% Human Immunoglobulin 10% 18% 8.4% 29% 1.0% 2.6% 1. Includes Shandong and Guizhou Taibang but excluding Huitian

  12. Slide 12: Domestic Market Share

    o LL a Domestic Market Share Estimated [VIG CBPO Market Share in Chinta(Jan 11) Consolidated China Biologic market share based Shandong | Guizhou | Xi’an on output Taibang' | Taibang | Huitian? ne Plasma collection 3 15% centers Estimated annual plasma = collection volume (MT) Plasma manufacturing f

  13. Slide 13: New Product Pipeline

    ® New Product Pipeline Registration, Filing and Products Preclinical © Phase] Phase ll_— Phase lll Cormercialization Human Prothrombin Complex Concentrate 2011 2011 Human Coagulation Factor Vill Human Hepatitis B Immunoglobulin (-14) gus for Intravenous Injection Human Fibrinogen z= Varicella Hyperm

  14. Slide 14: New Product Pipeline

    @ ©@ New Product Pipeline Products Development Status Human Prothrombin Complex Concentrate Approved to commence clinical trial (stage 9) Commercial production expected in 1H 20114 Human Coagulation Factor VIII Approved to commence clinical trial (stage 9) Commercial production expected in IH 2011 H

  15. Slide 15: R&D Objectives

    R&D Objectives On-going R&D Objectives v Expand portfolio of plasma-based biopharmaceutical products ¥ Maximize manufacturing efficiency and safety ¥ Promote product safety through implementation of new technologies v Refine production technology on existing products & China Biologic Products, Inc.

  16. Slide 16: Management Profiles

    @ Management Profiles Mr. Chao Ming Zhao, CEO of China Biologic Products * More than 10 years of experience in finance, accounting, and internal control * Certified Accountant in PRC and an international registered internal auditor * MBA in Finance from Chinese University of Hong Kong. Mr. Stanley L

  17. Slide 17: A profitable, rapidly growing plasma-based biopharmaceutical products company in China

    © ’, China Biologic Products, Inc. A profitable, rapidly growing plasma-based biopharmaceutical products company in China

  18. Slide 18: Strong Revenue Growth

    @O@ Strong Revenue Growth 19.0 2009 [ll Revenue from Guizhou Talbang THE Revenue from Shandong Taibang & China Biologic Products, Inc. 18

  19. Slide 19: Attractive Gross Margin

    ~ @ Attractive Gross Margin $ in Mi coz Ca rz 722% adios eoceeosoccos & China Biologic Products, Inc. 19

  20. Slide 20: Adjusted Net Income

    * Based on the adjusted Non-GAAP net income excluding $1.3 milion in non-cash compensation expenses 0 ** Based on the adjusted Non-GAAP net income excluding non-cash compensation expenses of $62,281, and §29,6 million related to the fair value of derivative iabilties ** 2010 adjusted net income guid

  21. Slide 21: Gross Profit, Operating Income and Adjusted Net Income

    2008 2007 Gross Profit $779 $59.0 $86.4 $32.7 $22.5 Gross Marg 4.9% 72.6 72.6% 0.0' 69.3 Operating Income $54.8 $40.6 $61.4 $20.3 $12.8 Adjusted Net Income $28.9" $20.0 $31.3°* $13.3" $8.2 * Based on the adjusted net income excluding non-cash compensation expenses of $661,653, incame of $9.9 million

  22. Slide 22: Selected Balance Sheet

    = @ Selected Balance Sheet , oa —— Cash and cash equivalents Total Current Assets Total Current Liabilities other liabilities Total Shareholders’ Equity 123.4 95.5 48.1 51.1 93.8 49.5 © logic Products, Inc. 2

  23. Slide 23: Stock Price and Peer Comparison

    Stock Price Fy10 Company (12/31/2010) Revs (ti) Hualan Biological Engineering 002007 sz cnva8.39 ony 1,585 ony 1.42 [Being Tiantan Biological Products 600161 ss ony 22.89 ony 1,140 cnya.so {Shanghai RAAS Blood Products 0022522 cNy34.64 Ny 608 ony O.73 fost us. csL-aU AUD 36.28 AUD 4,486, 4c aUD1.88

  24. Slide 24: Future Growth Strategies

    Future Growth Strategies « Increase plasma collection through organic growth and acquisitions « Increase yields on existing products through investments and facilities, R&D and process modifications and upgrades « Broaden product portfolio through R&D investments and collaborations « Future acquisit

  25. Slide 25: China Biologic Products Inc. Contacts

    China Biologic Products Inc. Christensen Y. Tristan Kuo, CFO Kimberly Minarovich, Managing Director No.14 East Hushan Road New York +1 212 618 1978 Taian City, Shandong 271000 kminarovich@christensenir.com PRC Beijing +86 53 8620 2306 IR@chinabiologic.com Legal Counsel Independent Auditor Pillsbury

  26. Slide 26: Appendix: SFDA Approval Process

    ippendix: SFDA Approval Process — Overview of SFDA Approval Process for New Plasma Products Stage Est. Time (Months) 1 Planning stage 1 2 Feasibility study and assumption clarification 2 3 Develop scope and technique for testing the new medicine 6 4 Preparation of a virus inactivation report and sub

  27. Slide 27: Appendix: Reconciliation of Financial Measures

    jendix: Reconciliation of Financial Measures CHINA BIOLOGIC PRODUCTS, INC. AND SUBSIDIARIES RECONCILIATION OF NON-GAAP FINANCIAL MEASURES, FOR THE THREE MONTHS ENDED SEPTEMBER 30, 2010, AND 2009 Three Months Ended Three Months Ended Nine Months Ended, Nine Months Ended, September 30, 2010 September

  28. Slide 28: A profitable, rapidly growing plasma-based biopharmaceutical products company in China

    January 2011 © ’, China Biologic Products, Inc. A profitable, rapidly growing plasma-based biopharmaceutical products company in China

China Biologic Products — Investor Presentation (March 2011) on 6ix